Sound therapy & masking for Tinnitus: What Does the Evidence Show?
Sound Therapy
Current evidence
Widely used, low-risk, valued by many — but never proven better than placebo in controlled trials.
Evidence strength: Limited (2/5) · Tier 4 — symptom management/coping · Evidence independence: Primarily independent.
Background sound — noise, nature sounds, music, sound generators or apps — used to partially cover tinnitus, ease its intrusiveness, and help sleep and focus.
Did tinnitus loudness improve?
None shown. No controlled evidence that sound therapy durably reduces the percept. Newer music-therapy meta-analyses report loudness improvements, but from low-quality trials.
Did tinnitus distress improve?
Limited. Cochrane 2018: NO usable trial data exist for sound therapy vs waitlist/placebo/information — the central question has simply never been answered; the 8 trials (N=590) only compared device types, with no differences found. Guideline status: 'Option'. Many individuals still find it genuinely helpful day to day.
Loudness means the tinnitus percept itself became quieter (psychoacoustic matching or loudness ratings). Distress means questionnaire scores such as THI/TFI, sleep, anxiety or quality of life improved — the sound may be unchanged. A THI/TFI improvement is never evidence the tinnitus got quieter.
How strong is the evidence?
Score 2/5 CONFIRMED after formal re-evaluation of the MOST trial (N=440, the largest double-blind sound-therapy RCT, eClinicalMedicine 2025): all four active sound arms improved similarly; the customized (DFCRS) arm beat unmodified music by only ~4 THI points (statistically significant, clinically small, no multiplicity adjustment) and the trial has no no-sound arm, so placebo effects cannot be excluded — the authors say so themselves. This is consistent with Cochrane 2018 (no strong evidence) and the guideline split (AAO-HNSF: option; NICE/EU: research-only; German S3: against sound generators). A large trial does not raise a rating by size alone; what it shows is modest, possibly non-specific benefit.
Has the result been independently replicated?
Conflicting results. Results discordant across independent trials; Cochrane 2018 found no strong evidence. The MOST trial (N=440, double-blind, 2025) found all active sound arms improved similarly, with a small advantage for customized modulation and no placebo arm — formally reviewed 2026-09-04, rating unchanged.
What are the limitations?
- The sound-therapy-vs-placebo question has never produced usable trial data (absence of evidence, not proof of no effect)
- Effects end when the sound stops
- Commercial products often oversell the science
What should patients know about safety?
Safety evidence: Strong. Very safe at comfortable volumes; keep sound below or at the tinnitus level rather than drowning it out.
Is it available?
Regulatory status: Guideline 'option'; consumer products unregulated. AAO-HNSF 2014 lists sound therapy as an option (benefit/harm balance, medium-quality evidence).
Availability: Free apps to clinical sound generators · Europe: Same · Cost (approx.): Free–$500 (bedside/wearable generators)
What the studies found
Sound therapy (amplification devices and sound generators) for tinnitus (Cochrane Review)
Sereda M, et al. · Cochrane Database of Systematic Reviews · 2018 · N=590 (8 trials) · Systematic review of RCTs
Crucially: NO usable data existed for any of the three main comparisons (sound therapy vs waitlist, vs placebo, or vs education alone). The 8 trials only compared device types — hearing aids vs sound generators vs combination devices — with insufficient evidence of any difference (low/very-low certainty).
This is absence of evidence, not 'tested and found no better': trials answering the sound-therapy-vs-placebo question simply have not produced usable data. Sound remains widely used, low-risk, and valued by many patients.
TRTT: Tinnitus Retraining Therapy vs standard of care
Scherer RW, Formby C, et al. · JAMA Otolaryngology–Head & Neck Surgery · 2019 · N=151 · Multicenter placebo-controlled RCT (6 US military hospitals)
TRT was not superior to standard of care — all three arms improved substantially (within-group TQ effect sizes −1.32, −1.16, −1.01) with few between-group differences. 77.5% (86/111 with data) achieved ≥7-point TQ reduction at 18 months.
Follow-up analyses attribute most benefit to the counseling component, not the sound generators.
MOST trial: modified sound therapy, 4-arm double-blind RCT (DFCRS arm)
Tang D, Gu D, Gong J, et al. · eClinicalMedicine · 2025 · N=440 randomized (UM 111 / UM+NBN 110 / HFEM 108 / DFCRS 111), all ITT · 4-arm multicentre double-blind RCT (participants + clinicians blinded); daily 2-h listening for 9 months; NO no-treatment or sham arm — unmodified music (UM) is the reference
The largest double-blind sound-therapy RCT. Only 1 of 440 participants reached complete remission. All arms improved (overall THI median 50→35, p<0.0001 — within-group). Between arms (GEE vs unmodified music): the customized DFCRS arm was better by −4.37 THI points [95% CI −6.25, −2.48], p<0.0001 — statistically significant but SMALL; fixed high-frequency enhancement (HFEM) was WORSE than unmodified music (+2.11, p=0.039); narrowband-noise mixing added nothing (p=0.75).
VAS-loudness fell in ALL arms (DFCRS greater in the first 3 months); the design cannot separate sound-specific benefit from placebo/natural fluctuation — the authors say so explicitly. No multiplicity adjustment. No adverse events in any group. ChiCTR2000039007; Chinese public funding; no competing interests declared. Registered on ChiCTR — invisible to CTgov-only discovery (audit finding).
AAO-HNSF Clinical Practice Guideline: Tinnitus
Tunkel DE, Bauer CA, Sun GH, et al. · Otolaryngology–Head and Neck Surgery · 2014 · N=Guideline (23-author multidisciplinary panel) · Clinical practice guideline (US)
RECOMMENDS: hearing-aid evaluation (with hearing loss) and CBT for persistent bothersome tinnitus. OPTION: sound therapy ('may recommend'). AGAINST routine use: medical therapy (antidepressants, anticonvulsants, anxiolytics, intratympanic drugs), dietary supplements (Ginkgo, melatonin, zinc), and rTMS. NO RECOMMENDATION: acupuncture.
Guidelines are consensus documents, not new trial data. Where the three major guidelines disagree — chiefly on sound therapy (AAO-HNSF: option; NICE and the European guideline: research-only; the German S3 guideline: against sound generators) — this platform shows the disagreement rather than picking a side. Statement strengths read from the published abstracts; full-text verbatim wording not independently re-read.
NICE guideline NG155: Tinnitus — assessment and management
National Institute for Health and Care Excellence · NICE (UK) · 2020 · N=National guideline · Clinical practice guideline (UK)
Amplification: OFFER with hearing loss affecting communication; CONSIDER with hearing loss without communication difficulty; DO NOT OFFER without hearing loss. Psychological therapies (stepped): digital tinnitus-related CBT → group interventions (MBCT/ACT/CBT) → individual CBT. Betahistine: 'Do not offer betahistine to treat tinnitus.' Sound therapy and neuromodulation: 'We were unable to make recommendations for practice in this area.'
Also advises against psychoacoustic pitch/loudness matching for assessment. Read from the official NICE pathway document (NBK557037 mirror). NICE's sound-therapy position (no practice recommendation) conflicts with AAO-HNSF's 'option' — shown as a disagreement, not resolved by this platform.
European multidisciplinary guideline for tinnitus
Cima RFF, Mazurek B, Haider H, et al. · HNO · 2019 · N=Multinational guideline · Clinical practice guideline (Europe)
CBT: STRONG recommendation FOR. Hearing aids: FOR, with hearing loss. Sound therapy: recommendation for RESEARCH only (no practice recommendation — not an 'against'). Pharmacotherapy: weak recommendation AGAINST. Transcranial electrical stimulation: AGAINST.
Stances verified via a peer-reviewed secondary source (Langguth et al., J Clin Med 2023, PMC10178961) because the primary full text is paywalled; verbatim wording and grading system therefore marked unable-to-verify. Together with AAO-HNSF 2014 and NICE NG155, the three guidelines agree on CBT (for) and drugs (against) and diverge on sound therapy.
Related clinical trials
Tracked trials are research in progress, not recommended treatments.
Related treatments
- Notched sound / notched music therapy — Music with your tinnitus frequency carved out — a modest, unconfirmed loudness effect in tonal tinnitus.
- Levo System (sleep-time sound matching) — FDA-cleared sound therapy played during sleep, matched to your tinnitus 'sound print' — one small positive…
- Neuromonics (and other discontinued cleared devices) — A once heavily marketed $5,000 'acoustic desensitization' program — FDA-cleared, weakly evidenced, now…
Evidence last reviewed: 2026-09-03 · Evidence included through: 2026-09-03 · Confidence: high. Open the interactive evidence profile.
This page summarizes published research for education. It is not medical advice; it cannot say what will work for any individual. Discuss treatment decisions with a qualified clinician.